Polycythemia vera (PV) Program in Pharmaceutical Benefits Scheme (PBS) 012-25080641
Expand allThis document outlines details of PBS-subsidised PBS-subsidised ruxolitinib for patients with polycythemia vera (PV).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
Polycythemia vera (PV) quick reference
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial PB388 form |
Written Electronic S85: ruxolitinib |
No |
OPA |
Not specified |
Yes |
|
Balance of initial (up to 48 weeks) |
Telephone Electronic S85: ruxolitinib |
No |
OPA |
Not specified |
Yes |
|
First continuing |
Telephone Electronic S85: ruxolitinib |
No |
OPA |
Not specified |
Yes |
|
Subsequent continuing |
Telephone Electronic S85: ruxolitinib |
No |
OPA |
Not specified |
Yes |